title: CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.
abstract: BACKGROUND
  We aimed to identify clinical characteristics of ovarian mature cystic teratoma (MCT) in association with CA19-9 elevation, and to determine if CA19-9 is a useful marker in discrimination of MCT from ovarian cancer (OC).
  
  
  METHODS
  Medical records of 322 women with pathologically-confirmed MCT or OC (stage 1 or 2) were reviewed retrospectively. The relationships between the characteristics of MCT (mean diameter, bilaterality, and pathologic components) and elevated CA19-9 were evaluated. Tumor markers in MCT were compared to those in OC.
  
  
  RESULTS
  MCTs with CA19-9 elevation were correlated with a larger diameter (8.53±3.84 cm vs. 6.95±3.97 cm, p=0.002) and presence of fat component (67.1% vs. 32.9%, p<0.001), compared to those with normal CA 19-9. Although the incidence of CA19-9 elevation was not different between patients with MCT and OC (p=0.700), the mean value of CA19-9 was higher in those with OC (114.66±20.66 U/mL vs. 508.58±261.63 U/mL, p=0.013). In addition, simultaneous elevation of CA125 and CA19-9 was associated with a higher probability of malignant neoplasm (p<0.001; odds ratio: 23.7; 95% confidence interval: 8.863-63.576) than single elevation of CA 19-9.
  
  
  CONCLUSIONS
  CA19-9 could be an important tool in the diagnosis of ovarian mature cystic teratoma. CA19-9, in combination with CA125, might be a useful marker in discrimination of MCT from cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Hallym University Dongtan Sacred Heart Hospital, Hwasung, Gyeonggido, Korea.
authors.forename: Hye-yon
authors.initials: HY
authors.lastname: Cho
authors.forename: Kidong
authors.initials: K
authors.lastname: Kim
authors.forename: Yong-Tark
authors.initials: YT
authors.lastname: Jeon
authors.forename: Yong-Beom
authors.initials: YB
authors.lastname: Kim
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: No
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D013724:Teratoma / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology
chemical_list: D018394:CA-125 Antigen; D018395:CA-19-9 Antigen
references.citation: Cancer. 1990 Feb 1;65(3):573-7
references.pmid: 2404560
references.citation: Hum Reprod. 1989 Jan;4(1):1-12
references.pmid: 2651469
references.citation: Tohoku J Exp Med. 1994 Feb;172(2):133-8
references.pmid: 8073424
references.citation: Arch Gynecol Obstet. 2009 Feb;279(2):145-7
references.pmid: 18506458
references.citation: Eur J Obstet Gynecol Reprod Biol. 2000 Feb;88(2):153-7
references.pmid: 10690674
references.citation: Gynecol Oncol. 2005 Nov;99(2):267-77
references.pmid: 16061277
references.citation: BMJ. 1996 Nov 30;313(7069):1355-8
references.pmid: 8956699
references.citation: Obstet Gynecol. 1991 Apr;77(4):580-5
references.pmid: 2002982
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):189-93
references.pmid: 16445632
references.citation: Radiology. 1985 May;155(2):477-8
references.pmid: 3885313
references.citation: Lancet. 1999 Apr 10;353(9160):1207-10
references.pmid: 10217079
references.citation: Clin Exp Obstet Gynecol. 2008;35(2):137-9
references.pmid: 18581770
references.citation: Eur J Radiol. 2009 Dec;72(3):454-63
references.pmid: 18804932
references.citation: Obstet Gynecol. 1995 Jan;85(1):48-52
references.pmid: 7800323
references.citation: Cancer. 1998 Jun 1;82(11):2249-55
references.pmid: 9610706
references.citation: Eur J Obstet Gynecol Reprod Biol. 1993 Apr;49(1-2):93-8
references.pmid: 8365529
references.citation: Int J Biol Markers. 2009 Jan-Mar;24(1):52-6
references.pmid: 19404923